Enliven Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic from Q2 2021 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Enliven Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Basic history and growth rate from Q2 2021 to Q3 2024.
  • Enliven Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending September 30, 2024 was 48.3M shares, a 17.6% increase year-over-year.
  • Enliven Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 35.5M shares, a 1038% increase from 2022.
  • Enliven Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 3.12M shares, a 35.5% increase from 2021.
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 48.3M +7.24M +17.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-13
Q2 2024 48.1M +7.11M +17.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 42M +1.08M +2.65% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 35.5M +32.4M +1038% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 41M +37.8M +1171% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 41M +37.9M +1220% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 41M +38.1M +1324% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-13
Q4 2022 3.12M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 3.23M -21.7M -87% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 3.1M -14.6M -82.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 2.88M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q3 2021 24.9M Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-25
Q2 2021 17.7M Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.